Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Vita 34 AG (V3V) NPV

Sell:€15.90 Buy:€16.05 Change: €0.25 (1.60%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: €0.25 (1.60%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: €0.25 (1.60%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vita 34 AG, is a Germany-based company that operates as an umbilical cord blood bank. It operates through the Stem Cell Storage and the Biotechnology segment. The Stem Cell Storage segment collects, processes, and stores stem cells from umbilical cord blood and umbilical cord tissue, as well as develops cell therapy procedures. The Biotechnology segment develops biological processes for cell and tissue culture, as well as employs them in the optimization and multiplication of cells and plants. It offers VitaPlusDonation that offers parents an alternative to the purely autologous storage or allogenic donation of umbilical cord blood; and Sibling Initiative program, which allows the storage free of charge of stem cells from the umbilical cord of a child whose brother or sister is seriously ill. The Company also provides prevention screening that helps to detect genetically related health risks and predispositions.

Contact details

Deutscher Platz 5a
+49 (341) 4879240

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€65.71 million
Shares in issue:
4.10 million
Health Care Services
Frankfurt Stock Exchange

Key personnel

  • Frank Koehler
    Chairman of the Supervisory Board
  • Wolfgang Knirsch
    Chairman of the Management Board, Chief Executive Officer
  • Falk Neukirch
    Chief Financial Officer, Member of the Management Board
  • Alexander Starke
    Member of the Management Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.